ブドウ球菌感染症医薬の世界市場2019-2023

Technavioが発行した調査報告書(IRTNTR31241)
◆英語タイトル:Global Staphylococcal Infection Drugs Market 2019-2023
◆商品コード:IRTNTR31241
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年4月29日
◆ページ数:126
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、ブドウ球菌感染症医薬の世界市場について調査・分析し、市場概要、市場環境、ブドウ球菌感染症医薬市場規模、製品別(βラクタム、ペプチド、キノロン、マクロライド、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・ブドウ球菌感染症医薬の世界市場概要
・ブドウ球菌感染症医薬の世界市場環境
・ブドウ球菌感染症医薬の世界市場動向
・ブドウ球菌感染症医薬の世界市場規模
・ブドウ球菌感染症医薬の世界市場:業界構造分析
・ブドウ球菌感染症医薬の世界市場:製品別(βラクタム、ペプチド、キノロン、マクロライド、その他)
・ブドウ球菌感染症医薬の世界市場:地域別市場規模・分析
・ブドウ球菌感染症医薬の北米市場規模・予測
・ブドウ球菌感染症医薬のヨーロッパ・中東・アフリカ市場規模・予測
・ブドウ球菌感染症医薬のアジア太平洋市場規模・予測
・ブドウ球菌感染症医薬の主要国分析
・ブドウ球菌感染症医薬の世界市場:意思決定フレームワーク
・ブドウ球菌感染症医薬の世界市場:成長要因、課題
・ブドウ球菌感染症医薬の世界市場:競争環境
・ブドウ球菌感染症医薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market. Technavio’ s analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.
Market Overview
Increasing incidence of staphylococcal infections
The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.
Lack of vaccines and new drug classes
Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.
For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures. Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Beta-lactams – Market size and forecast 2018-2023
• Peptides – Market size and forecast 2018-2023
• Quinolones – Market size and forecast 2018-2023
• Macrolides – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Allergan Plc
• Bayer AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of vendors classification
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Beta-lactams – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Beta-lactams – Year-over-year growth 2019-2023 (%)
Exhibit 21: Peptides – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Peptides – Year-over-year growth 2019-2023 (%)
Exhibit 23: Quinolones – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Quinolones – Year-over-year growth 2019-2023 (%)
Exhibit 25: Macrolides – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Macrolides – Year-over-year growth 2019-2023 (%)
Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: North America – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in North America
Exhibit 42: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 43: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in Europe
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc – Vendor overview
Exhibit 54: Allergan Plc – Business segments
Exhibit 55: Allergan Plc – Organizational developments
Exhibit 56: Allergan Plc – Geographic focus
Exhibit 57: Allergan Plc – Segment focus
Exhibit 58: Allergan Plc – Key offerings
Exhibit 59: Bayer AG – Vendor overview
Exhibit 60: Bayer AG – Business segments
Exhibit 61: Bayer AG – Organizational developments
Exhibit 62: Bayer AG – Geographic focus
Exhibit 63: Bayer AG – Segment focus
Exhibit 64: Bayer AG – Key offerings
Exhibit 65: GlaxoSmithKline Plc – Vendor overview
Exhibit 66: GlaxoSmithKline Plc – Business segments
Exhibit 67: GlaxoSmithKline Plc – Organizational developments
Exhibit 68: GlaxoSmithKline Plc – Geographic focus
Exhibit 69: GlaxoSmithKline Plc – Segment focus
Exhibit 70: GlaxoSmithKline Plc – Key offerings
Exhibit 71: Merck & Co. Inc. – Vendor overview
Exhibit 72: Merck & Co. Inc. – Business segments
Exhibit 73: Merck & Co. Inc. – Organizational developments
Exhibit 74: Merck & Co. Inc. – Geographic focus
Exhibit 75: Merck & Co. Inc. – Segment focus
Exhibit 76: Merck & Co. Inc. – Key offerings
Exhibit 77: Pfizer Inc. – Vendor overview
Exhibit 78: Pfizer Inc. – Business segments
Exhibit 79: Pfizer Inc. – Organizational developments
Exhibit 80: Pfizer Inc. – Geographic focus
Exhibit 81: Pfizer Inc. – Segment focus
Exhibit 82: Pfizer Inc. – Key offerings
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of vendors classification



【掲載企業】

Allergan Plc、Bayer AG、GlaxoSmithKline Plc、Merck & Co. Inc.、Pfizer Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ブドウ球菌感染症医薬の世界市場2019-2023(Global Staphylococcal Infection Drugs Market 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆